0000000000017203

AUTHOR

H. Mayer

showing 2 related works from this author

Heterogeneous response to differentiation induction with different polar compounds in a clonal rat rhabdomyosarcoma cell line (BA-HAN-1C)

1989

The clonal rat rhabdomyosarcoma cell line BA-HAN-1C was tested for its susceptibility to differentiation induction with different polar compounds. This cell line is composed of proliferating mononuclear tumour cells, some of which spontaneously fuse to form terminally differentiated postmitotic myotube-like giant cells. Exposure of BA-HAN-1C cells to dimethylsulphoxide (DMSO), hexamethylene bisacetamide (HMBA), sodium butyrate (NaBut) and N-monomethylformamide (NMF) resulted in a significant inhibition of proliferation (P less than 0.001) and in a simultaneous increase in differentiation. The response was most pronounced after exposure to NMF as evidenced by a marked increase in the creatin…

Cancer ResearchCellular differentiationAntineoplastic AgentsBiologyPeripheral blood mononuclear cellHexamethylene bisacetamideCell LineCell Fusionchemistry.chemical_compoundAcetamidesRhabdomyosarcomaTumor Cells CulturedAnimalsDimethyl SulfoxideCreatine KinaseCell fusionFormamidesDimethyl sulfoxideCell DifferentiationSodium butyrateMolecular biologyClone CellsRatsButyratesOncologychemistryBiochemistryCell cultureGiant cellButyric AcidResearch ArticleBritish Journal of Cancer
researchProduct

Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.

2006

Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatm…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRenal functionCyclosporinsDermatologyPharmacologyGastroenterologyDrug Administration ScheduleDouble-Blind MethodInternal medicinePsoriasismedicineHumansPsoriasisAdverse effectBody surface areaChemotherapyDose-Response Relationship Drugbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseTolerabilityToxicityFemalebusinessImmunosuppressive AgentsFollow-Up StudiesThe British journal of dermatology
researchProduct